Vital Chemtech Appoints Two Independent Directors After Exits

Vital Chemtech Limited appointed Bhavik Shirish Pandit and Mukeshkumar Ganeshbhai Kanazariya as Non-Executive Independent Directors for five-year terms effective November 3, 2026, replacing two independent directors who resigned on the same date. The appointments remain subject to shareholder approval.

Why did Vital Chemtech change its independent directors?

Vital Chemtech made the board changes after its Nomination and Remuneration Committee recommended the appointments of two additional directors in the non-executive, independent category. The board approved the appointment of Bhavik Pandit and Mukeshkumar Kanazariya with effect from November 3, 2026.

At the same time, independent directors Ajay Kumar Agrawal and Deepakkumar Kushalchandra Chaubisa resigned. The company said Agrawal resigned for personal reasons, while Chaubisa cited professional preoccupations. The disclosure stated that the incoming directors would take office on the same date as the departing directors.

The filing was a board-outcome disclosure and did not contain financial figures, changes in business guidance, or any operational announcement. It was primarily a governance update concerning the composition of the board.

Who are the directors joining and leaving Vital Chemtech?

Bhavik Pandit and Mukeshkumar Kanazariya have been appointed as Additional Non-Executive Independent Directors. Each appointment is for five consecutive years from November 3, 2026, and the directors will not be liable to retire by rotation during their stated terms.

The appointments require shareholder approval at the next general meeting or within three months, whichever occurs earlier. Until that approval process is completed, the appointments remain subject to the conditions described in the company’s disclosure.

Ajay Kumar Agrawal and Deepakkumar Chaubisa were the two outgoing independent directors. Chaubisa had been listed as a director and board member since June 3, 2022. The company separately reported that Vivek Dinesh Nathwani was appointed as an Additional Non-Executive Independent Director from May 30, 2025, and shareholders regularised that appointment at the annual general meeting held on September 27, 2025.

What is the background to Vital Chemtech's board changes?

Vital Chemtech has reported several board and management changes in recent years. As of March 31, 2026, the company said its board had six members, comprising two executive directors, one non-executive director and three independent directors.

During the financial year covered by its annual disclosures, Vivek Nathwani joined as an Additional Non-Executive Independent Director from May 30, 2025. In the same period, Suneel Mundra resigned as an Additional Non-Executive Independent Director from May 30, 2025, citing personal and unavoidable circumstances.

The company also changed the designation of Sangeeta Vipul Bhatt from Whole-Time Director to Non-Executive and Non-Independent Director from June 14, 2025. That change was subsequently approved by shareholders at the company’s fourth annual general meeting on September 27, 2025.

Earlier management updates include the appointment of Jitendra Raval as Chief Financial Officer from August 15, 2026. The latest independent-director transition is therefore part of a wider set of disclosed leadership and board changes, rather than a financial result or operational development.

What does the change mean for shareholders and investors?

For shareholders, the immediate issue is the approval process for the two incoming independent directors. Vital Chemtech has stated that approval will be sought at the next general meeting or within three months, whichever is earlier. The appointments are for five-year terms if shareholders approve them.

Independent directors are non-executive board members and form part of the board’s governance structure. In this case, the company has disclosed a simultaneous transition: two directors left and two new independent directors were appointed with the same effective date. The filing does not state any change to the company’s financial targets, revenue, profitability, production, or capital allocation plans.

The announcement also follows the board’s September 2026 approval to seek shareholder consent for the re-appointment of Vipul Jatashanker Bhatt as Chairman and Managing Director and Jay Vipul Bhatt as Whole-Time Director. Both proposed executive re-appointments cover five years from September 28, 2026, to September 27, 2031.

How does this appointment fit into corporate governance requirements?

The appointments show the board using its Nomination and Remuneration Committee process before appointing additional independent directors. The company has also specified the proposed tenure, the effective date, the non-executive independent classification, and the requirement for subsequent shareholder approval.

The distinction between the new appointments and the executive re-appointments is relevant. Pandit and Kanazariya are stated to be not liable to retire by rotation for their five-year independent-director terms. Vipul Bhatt and Jay Bhatt, in contrast, were disclosed as liable to retire by rotation in connection with their proposed five-year re-appointments.

For investors tracking governance matters, the next formal milestone is the shareholder decision on the two appointments. The company’s November 2 disclosure does not provide additional details on financial performance or expected business impact from the board changes.

Conclusion

Vital Chemtech has replaced two outgoing independent directors with Bhavik Pandit and Mukeshkumar Kanazariya, both appointed from November 3, 2026 for proposed five-year terms. The simultaneous resignations and appointments make the disclosure principally a board-composition and corporate-governance update, with no financial amounts or operational revisions announced.

The next item to watch is shareholder approval for the two independent-director appointments, which must be obtained at the next general meeting or within three months, whichever is earlier. Investors may also monitor the approval process for the proposed five-year re-appointments of Vipul Bhatt and Jay Bhatt.